Literature DB >> 18598229

Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases.

Hayrettin Tumani1, Charlotte Teunissen, Sigurd Süssmuth, Markus Otto, Albert C Ludolph, Johannes Brettschneider.   

Abstract

Chronic neurological diseases (CND) like amyotrophic lateral sclerosis (ALS), dementia or multiple sclerosis (MS) share a chronic progressive course of disease that frequently leads to the common pathological pathway of neurodegeneration, including neuroaxonal damage, apoptosis and gliosis. There is an ongoing search for biomarkers that could support early diagnosis of CND and help to identify responders to interventions in therapeutic treatment trials. Cerebrospinal fluid (CSF) is a promising source of biomarkers in CND, since the CSF compartment is in close anatomical contact with the brain interstitial fluid, where biochemical changes related to CND are reflected. We review recent advances in CSF biomarkers research in CND and thereby focus on markers associated with neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598229     DOI: 10.1586/14737159.8.4.479

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  24 in total

Review 1.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

2.  The chaperone protein clusterin may serve as a cerebrospinal fluid biomarker for chronic spinal cord disorders in the dog.

Authors:  Intan N F Shafie; Mark McLaughlin; Richard Burchmore; Mary Ann A Lim; Paul Montague; Pamela E J Johnston; Jacques Penderis; Thomas J Anderson
Journal:  Cell Stress Chaperones       Date:  2013-08-29       Impact factor: 3.667

3.  Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases.

Authors:  Sarah Jesse; Johannes Brettschneider; Sigurd D Süssmuth; Bernhard G Landwehrmeyer; Christine A F von Arnim; Albert C Ludolph; Hayrettin Tumani; Markus Otto
Journal:  J Neurol       Date:  2010-12-25       Impact factor: 4.849

Review 4.  CSF markers in amyotrophic lateral sclerosis.

Authors:  Joanna Tarasiuk; Alina Kułakowska; Wiesław Drozdowski; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2012-05-04       Impact factor: 3.575

5.  N-Glycan Profile of Cerebrospinal Fluids from Alzheimer's Disease Patients Using Liquid Chromatography with Mass Spectrometry.

Authors:  Byeong Gwan Cho; Lucas Veillon; Yehia Mechref
Journal:  J Proteome Res       Date:  2019-09-16       Impact factor: 4.466

6.  1H-NMR-based metabolomic profiling of CSF in early amyotrophic lateral sclerosis.

Authors:  Hélène Blasco; Philippe Corcia; Caroline Moreau; Ségolène Veau; Clémentine Fournier; Patrick Vourc'h; Patrick Emond; Paul Gordon; Pierre-François Pradat; Julien Praline; David Devos; Lydie Nadal-Desbarats; Christian R Andres
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

Review 7.  Glycoproteomics in neurodegenerative diseases.

Authors:  Hyejin Hwang; Jianpeng Zhang; Kathryn A Chung; James B Leverenz; Cyrus P Zabetian; Elaine R Peskind; Joseph Jankovic; Zhen Su; Aneeka M Hancock; Catherine Pan; Thomas J Montine; Sheng Pan; John Nutt; Roger Albin; Marla Gearing; Richard P Beyer; Min Shi; Jing Zhang
Journal:  Mass Spectrom Rev       Date:  2010 Jan-Feb       Impact factor: 10.946

8.  CSF phospho-tau is independent of age, cognitive status and gender of neurological patients.

Authors:  Armin Scheurich; Peter P Urban; Nassrin Koch-Khoury; Andreas Fellgiebel
Journal:  J Neurol       Date:  2009-11-17       Impact factor: 4.849

9.  Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies.

Authors:  Patrick Oeckl; Fabian Metzger; Magdalena Nagl; Christine A F von Arnim; Steffen Halbgebauer; Petra Steinacker; Albert C Ludolph; Markus Otto
Journal:  Mol Cell Proteomics       Date:  2016-08-09       Impact factor: 5.911

10.  Biomarkers in the clinical diagnosis and management of traumatic brain injury.

Authors:  Georgene W Hergenroeder; John B Redell; Anthony N Moore; Pramod K Dash
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.